Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Efficacy And Safety Of Sitagliptin For The Treatment Of New-Onset Diabetes After Renal Transplantation., Brian P. Boerner, Clifford D. Miles, Vijay Shivaswamy
Efficacy And Safety Of Sitagliptin For The Treatment Of New-Onset Diabetes After Renal Transplantation., Brian P. Boerner, Clifford D. Miles, Vijay Shivaswamy
Journal Articles: Diabetes, Endocrinology & Metabolism
New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to concerns about renal dysfunction and risk for lactic acidosis. Therefore, alternative first-line agents for the treatment of NODAT in renal transplant recipients are needed. Sitagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, has a low incidence of hypoglycemia, is weight neutral, and, in a small study, did not affect immunosuppressant levels. However, long-term sitagliptin use for the treatment of NODAT in kidney transplant recipients has not been studied. …